Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD

Elizabeth BrÃ©m, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD at MOASCs Spotlight On Hematology in Huntington Beach 2018.

Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia